per-chart, page-1131

New coverage appeared in LinkedIn;

Quote
Percheron Therapeutics Limited has continued to feature in news media this week.In a broad-ranging interview with Livewire Markets, Dr Shane Storey and Dr Melissa Benson at Wilsons Advisory spoke to Sara Allen about value opportunities in the Australian biotech sector.Dr Benson named Percheron one of three stocks at the top of her watchlist, and noted the upcoming readout from the company's phase IIb clinical trial in Duchenne muscular dystrophy."In the case of Percheron, they have an all-important clinical trial readout in December that we have waited several years for! If we see that their drug is able to help boys with a rare disease, Duchenne muscular dystrophy, retain their upper limb function it could set up potential European approvals and open up discussions with US regulators about expanding their trial/access."
Unquote